United States: The CMS Final Covered Outpatient Drug Rule Addresses Many Industry Concerns

Last Updated: February 4 2016
Article by Donna Lee Yesner and Stephen E. Ruscus

The rule implementing the Medicaid Drug Rebate Program is less burdensome and costly than what was originally proposed.

In 2010, the Affordable Care Act (ACA) directed the US Centers for Medicare and Medicaid Services (CMS) to publish a rule for calculating Average Manufacturer Price (AMP), which is used to determine both the Medicaid rebate amount and the payment rate for multiple-source drugs. CMS interpreted the ACA mandate as authorizing CMS to address all aspects of the Medicaid Drug Rebate Program (MDRP) treatment of covered outpatient drugs, and on January 21, 2016, nearly four years after publishing its proposed rule, CMS finalized the rule, which will take effect April 1, 2016.1 The Final Rule implements changes to AMP that the ACA required, replaces the calculation methodology for AMP in the withdrawn Deficit Reduction Act (DRA) rule,2 and provides additional rules for determining Best Price (BP) reported for innovator drugs and biological products.

The provisions that have the most effect on manufacturers, in terms of rebate liability or operational challenges, are

  • permission for manufacturers to continue presuming that drugs sold to wholesalers are distributed to retail community pharmacies (RCPs) unless chargeback data indicate indirect sales to a different class of trade;
  • the method for calculating AMP for infusion, inhalation, instilled, implanted, and injected drugs generally dispensed through RCPs (5i AMP);
  • inclusion of federal territories in the definition of "United States";
  • treatment of specialty pharmacies;
  • treatment of generic drugs marketed under a paper New Drug Approval (NDA) or section 505(b)(2);
  • exclusion of prices charged 340B entities from BP;
  • BP treatment of discounts, rebates, and fees provided to multiple parties on the same unit;
  • implementation of the alternative additional rebate for line extensions; and
  • revision of Base Date AMP.

The "Presumed Inclusion" Method for Determining Indirect RCP Sales

AMP is defined to include prices paid to manufacturers by wholesalers for units that the wholesalers distributed to RCPs and prices paid by RCPs that purchased directly from manufacturers. Prior to the ACA, AMP included prices paid by wholesalers for drugs distributed to the retail pharmacy class of trade, which CMS interpreted broadly. Because manufacturers have no visibility into wholesaler resale transactions, except when the resale to a contract customer of the manufacturer generates a wholesaler chargeback claim, since the beginning of the MDRP, CMS permitted manufacturers to presume that wholesaler sales are to retail pharmacies unless a manufacturer can identify and remove nonretail pharmacy sales through chargeback data.

The Final Rule takes a pragmatic approach, recognizing that manufacturers must certify the accuracy of the AMP calculation but lack access to complete, accurate, and verifiable sales data. In addition, if indirect sales to RCPs were not included because they could not be documented, there would likely be substantial under-inclusion, which would skew AMP. These concerns trumped CMS's initial concern that the "presumed inclusion" method would cause inclusion of some sales distributed to nonretail pharmacy customers. Therefore, the Final Rule does not require manufacturers to build up AMP from identifiable indirect sales to RCPs and exclude sales to wholesalers if they cannot be documented as distributed to RCPs. Operationally, this means that calculating AMP will be easier and identifying gross includable wholesaler sales will not be delayed until the end customer can be identified through wholesaler-provided data. Under the presumed inclusion method, gross wholesaler sales are included in AMP when they occur, with removal of excluded sales lagging behind and applied to current sales through a smoothing mechanism.

Clarity for Calculating 5i AMP Reduces Potential for Erratic Calculations and Inflation Penalties

The statutory definition of AMP excludes discounts and rebates to entities that do not conduct business as a wholesaler or RCP, except for five categories of drugs (infusion, inhalation, instilled, implanted, and injected) that are "not generally dispensed" by RCPs. The Final Rule establishes a methodology for calculating "5i" AMP by separately listing the included and excluded transactions and setting a standard for determining which of the two AMP methodologies apply to a particular drug.

Because AMP must be calculated and reported on a monthly basis, and the percentage of sales through RCPs can vacillate from month to month, the need to repeatedly switch methodologies is incredibly burdensome. Worse, if baseline AMP is calculated using the 5i method and quarterly AMP is later calculated using the retail method because the percentage of retail sales increased, that quarterly AMP will likely be higher, creating the appearance of a price increase when no increase was taken, which unfairly subjects a manufacturer to an inflation penalty. To determine whether a drug is not generally dispensed by RCPs and therefore subject to 5i AMP, the Final Rule establishes a threshold of 70% of units sold to other than RCPs, instead of the proposed 90%. That cushion, the use of units instead of dollars, and the ability to smooth the units over a longer period means that the volume of sales through RCPs is less likely to cross the line.

New Interpretation of "United States" to Include the Territories Will Increase Manufacturers' Rebate Liability

By statute, the MDRP is implemented through the terms of manufacturer rebate agreements, which set forth CMS's interpretation of the statutory requirements. Since the program's inception in 1990, CMS has interpreted the requirements to report prices paid to manufacturers in the United States and provide rebates on prescriptions paid by the United States to mean the 50 states and the District of Columbia. Accordingly, the rebate agreement defines "states" to reflect that interpretation.

In the Final Rule, CMS suddenly reversed itself and expanded the scope of the program to encompass the territories of Puerto Rico, the Virgin Islands, the Northern Mariana Islands, Guam, and American Samoa. The expanded volume of prescriptions on which Medicaid rebates are due will increase manufacturers' liability, but the new requirement to include transactions in the territories in the determination of AMP and BP will have a far greater impact. Prices in the territories are affected by laws and regulations inapplicable to the states, including single-payer systems and price controls, pricing structures that reflect foreign market considerations, and distribution arrangements that differ from those in the states.

Although the small percent of low-priced sales from the territories is unlikely to significantly affect a manufacturer's average price, even a single very low-priced transaction in a territory could establish a new BP for the relevant quarter. Thus, the differential between AMP and BP based on a single transaction in the territories could increase the unit rebate amount applicable to use in all 50 states and the District of Columbia. However, in recognition of serious manufacturer concerns relating to identification and inclusion of sales to the territories in manufacturer government pricing calculations (including the possibility that related transaction data might not currently reside in a manufacturer's government pricing systems or even its US sales systems), CMS has delayed implementation of this aspect of the Final Rule for one year, until April 1, 2017. The one-year delay also affords manufacturers sufficient time to revisit pricing strategies in the territories to minimize the increase in Medicaid rebate liability likely to occur.

Exclusion of Specialty Pharmacies from the Definition of RCP

The definition of RCP excludes pharmacies that dispense primarily through the mail. Some drugs, particularly those with risk evaluation and mitigation strategies, are distributed primarily through specialty pharmacies. Although CMS was concerned that some drugs that are not 5i drugs would have no AMP if specialty pharmacies are excluded from RCP, the Final Rule does not permit manufacturers to treat specialty pharmacies as RCPs unless they meet the statutory definition of RCP, even if AMP is based on a few number of sales. Although the Final Rule does not define what "primarily through the mail" means, manufacturers may reasonably assume it means a majority of their prescriptions. Further, for purposes of determining which AMP methodology to apply to 5i drugs, units sold to specialty pharmacies would be considered RCPs in computing the percentage of sales dispensed by RCPs only to the extent that they meet the statutory definition. Thus, manufacturers could consider specialty pharmacies that distribute a majority of drugs by mail to be nonretail in determining which methodology to use. Manufacturers must develop a means to reasonably identify whether specialty pharmacies, home health agencies, and similar providers qualify as RCPs.

Generic Drugs Marketed Under Paper NDAs and Certain 505(b)(2) Applications

The Medicaid rebate statute imposes fewer burdens and lower rebate percentages on noninnovator drugs than on Single-Source Drugs and Innovator Multiple-Source Drugs, defined as drugs "originally marketed under an original New Drug Application." Between 1962 and 1984, new duplicate drugs and drugs that rely on data not developed by an applicant were approved by the US Food and Drug Administration (FDA) using a process involving fewer requirements than the NDA process applied to the first application for that drug (so-called paper NDAs). This process was replaced, pursuant to the Hatch-Waxman Act, by the 505(b)(2) process that expressly permits FDA to rely on data not developed by the applicant, and the Abbreviated New Drug Application (ANDA) process under 505(j) for approval of duplicate drugs.

Although CMS previously interpreted the statute's definition of "Noninnovator Multiple-Source Drug" or "N Drug" as including drugs approved under both paper NDAs and NDAs approved under 505(b)(2), the Final Rule excludes both types of drugs from the definition of an N Drug. Drug Efficacy Study Implementation (DESI) drugs that have gone through the FDA approval process and received NDAs are also excluded; however, ANDAs that rely on DESI notices and were approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act prior to enactment of 505(j) will be treated as ANDAs if FDA so classifies them. In creating these distinctions, CMS interpreted an "original NDA" to be any NDA that the FDA approved for marketing, and "originally marketed" under an NDA to mean a drug that was initially marketed as a Single-Source Drug.

Notwithstanding its position on generic drugs approved under NDAs, CMS acknowledged that there might be circumstances under which drugs not marketed under ANDAs might be more appropriately treated as N Drugs. CMS specifically identified drugs approved under a paper NDA prior to the enactment of the Hatch-Waxman Amendments of 1984 and drugs approved under certain types of literature-based 505(b)(2) NDA approvals as candidates for application of this exception. Accordingly, manufacturers seeking application of the exception may submit materials to CMS for review and confirmation in writing that the product at issue can be treated as an N Drug. If a manufacturer is currently marketing a generic drug under some form of an NDA but treats it as an N Drug, CMS indicated that it will give the manufacturer four quarters after the Final Rule's effective date to apply for an exception before CMS will take administrative action for any noncompliance.

BP Excludes All Prices Available to 340B Covered Entities

The Medicaid statute expressly exempts from BP any price available to an entity that meets the definition of covered entity in section 340B of the Public Health Service Act.3 The exemption is not limited to drugs sold to these entities under the 340B program. Prior to expanding the 340B program in the ACA, the US Congress clarified its intent by indicating that drugs sold to 340B-eligible hospitals for inpatient use were exempt from BP, even though these drugs are not covered by the 340B program. The Final Rule applies that logic to all prices available to any entity described in section 340B, whether or not the drugs are purchased outside the 340B program, such as drugs provided to individuals who do not qualify as patients and orphan drugs, which the ACA excluded from the 340B program for newly added categories of hospitals. Administratively, this policy provides welcome relief to manufacturers because it will ease the burden of subclassifying purchases by 340B entities. For covered entities, it also removes a significant impediment to receiving discounts on non-340B drugs.

Improved Guidance on Treatment of Administrative Fees Paid to Third Parties

Group Purchasing Organizations (GPOs) and Pharmacy Benefit Managers (PBMs) negotiate prices and provide services to manufacturers but do not purchase drugs. Fees paid to these entities reduce a manufacturer's realization on a sale; however, they are not necessarily intended to reduce the price paid for the drug by a provider that is the beneficiary of the GPO or PBM agreement. Treatment of these fees is a particular concern for BP and 5i AMP, which do not exempt PBM rebates or prices paid by institutions under GPO agreements.

The Final Rule clarifies that price concessions are aggregated in BP only if provided to the same entity and that fees paid to third parties are only price concessions to the purchasers if they are passed through in whole or in part to the purchasers. Importantly, the Final Rule reconciles its guidance on Bona Fide Service Fees, which are exempt from AMP and BP, with its guidance on the treatment of these fees in the calculation of Average Sales Price under Medicare Part B. Accordingly, for all pricing calculations, manufacturers may presume such fees are not passed through to a customer or client of the recipient absent evidence or notice to the contrary. Otherwise, administrative fees paid to third parties would artificially reduce the amount actually paid by these providers. Nevertheless, there remain issues with respect to allocation of fees, agreements that reserve pass-through rights, and fees paid to entities with close corporate affiliations with providers. Manufacturers should consult with counsel before making reasonable assumptions in these areas.

Alternative Additional Rebate Formula Needs Clarity

rior to enacting the ACA, Congress was concerned that manufacturers were reformulating innovator drugs as extended release versions to extend the patent life and increase the price. To discourage this practice, the ACA required manufacturers to use an alternative additional rebate calculation (based on the original drug price increase) as an inflation penalty for line extensions of innovator oral solid drugs (defined to mean extended release formulations) if that method yielded a higher rebate amount than the normal calculation.

However, the Final Rule does not decide whether the term "line extension" is limited to extended release formulations. The Proposed Rule proposed to apply the term to all changes to an oral solid drug requiring FDA approval (except a new strength), including changes that provide real health benefits and reduce medication costs, such as improved delivery systems, abuse-deterrent formulations, combination drugs, and drugs approved under section 505(b)(2). Although the Final Rule did not resolve this issue, it did limit application of the requirements to manufacturers that report AMP for the original drug. Thus, companies acquiring the right to sell a new formulation need not obtain quarterly AMP from the company that continues to sell the old formulation.

Manufacturers May Recalculate Base Date AMP to Reflect Final Rule Changes

One principal purpose of the ACA's revision of the AMP calculation was to increase AMP. The effects of this included not only an increase in basic Medicaid rebates paid by manufacturers but also an increase in the inflation penalty paid for Single-Source Drugs and Innovator Multiple-Source Drugs because of the false appearance of price inflation created by the revised AMP definition. To account for this, the Final Rule adopts the Proposed Rule's provision for reporting revised ACA Base Date AMPs. This provision permits manufacturers to submit revised Base Date AMP calculations to CMS within the first four full calendar quarters following April 1, 2016. The Final Rule limits the scope of the recalculation to revisions to AMP as provided for in the Final Rule's definition of AMP. Manufacturers may choose to recalculate Base Date AMP on a product-by-product basis, but must use actual and verifiable pricing records in these recalculations. The decision to revise Base Date AMP depends on several factors, but manufacturers should consider the option before it expires.

Conclusion

The Final Rule contains numerous other provisions that affect manufacturers' policies and procedures for reporting prices for covered drugs. We recommend that manufacturers promptly review and update existing policies and procedures, document reasonable assumptions in implementing the Final Rule, and obtain advice of counsel where necessary to ensure compliance on the effective date.

Footnotes

1 This document was published in the Federal Register on February 1, 2016 and is available online at http://federalregister.gov/a/2016-01274. Some provisions in the Final Rule, such as extension of the MDRP to the territories, have later effective dates.

2 CMS withdrew portions of the DRA rule following the ACA’s enactment.

3 42 U.S.C. §1396r-8(c)(1)(C)(i)(I).

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.